.Pharmacolibrary.Drugs.C_CardiovascularSystem.C07F_BetaBlockingAgentsOtherCombinations.C07FX03_MetoprololAndAcetylsalic.MetoprololAndAcetylsalic .Pharmacolibrary.Drugs.C_CardiovascularSystem.C07F_BetaBlockingAgentsOtherCombinations.C07FX03_MetoprololAndAcetylsalic.MetoprololAndAcetylsalic| name: | MetoprololAndAcetylsalicylicAcid | |
| ATC code: | C07FX03 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 100 | mg |
| volume of distribution: | 200 | L |
| clearance: | 60 | L/hr |
| other parameters in model implementation | ||
Fixed combination of metoprolol (a selective beta-1 adrenergic blocker used for hypertension, angina, and heart failure) and acetylsalicylic acid (aspirin, an antiplatelet and anti-inflammatory agent for cardiovascular prevention). Intended to reduce blood pressure and risk of cardiovascular complications, generally for secondary prevention post-myocardial infarction or for cardiovascular risk reduction. This fixed-dose combination is approved in certain regions but not globally available as of 2024.
Pharmacokinetic parameters estimated from individual component data (metoprolol tartrate and acetylsalicylic acid) in healthy adults, as no published study reports PK parameters for the fixed combination product.